Research to shed new light on how statins benefit heart patients

A scientist at Leeds whose research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit cardiac patients, has secured funding to further investigate her findings.

Dr Sarah Calaghan from the University’s Faculty of Biological Sciences has been awarded £80,000 from Heart Research UK to progress her preliminary evidence that statins are directly affecting the heart muscle cell.

“For a long time the cardiovascular benefits of statins were considered to be due to reducing cholesterol in the blood, which prevents the build-up of plaques in arteries - a major cause of heart attacks and strokes. But more recently it’s becoming clear that this is not the only way statins work,” she says.

The widely acclaimed family of drugs are known to have beneficial effects for patients at risk of cardiovascular disease and those with established cardiovascular disease, saving up to 9,000 lives a year(1).

Dr Calaghan’s research suggests that statins are actually having a direct effect on heart cells, specifically the caveolae - tiny indentations in the cell membrane. Caveolae contain signalling molecules that Dr Calaghan has shown to have an active role in controlling the pumping mechanism of the heart.

“Caveolae need cholesterol to exist and our research has shown that if cholesterol is removed from the membrane then the caveolae will collapse. This disrupts the function of caveolae-based signalling molecules and affects the heart’s pumping mechanism and its ability to change its force of contraction,” she explains.

In a healthy person, the heart’s rate and force of contraction is increased by adrenaline during exercise or stress – producing what is known as the ‘fight or flight’ response.

“We know that statins are beneficial,” says Dr Calaghan. “But it’s really important to know exactly why and how they are affecting the heart cells, since the hearts of patients with cardiac disease respond differently to adrenaline than healthy hearts.

“Our new research hopes to determine exactly how statins affect caveolae and what impact this has on the way the heart behaves both at rest and during conditions of stress or exercise.”

“If we can do this it will help us to understand the disease process better, and this in turn has important implications for the development of new ways to treat heart diseases.”

Source: University of Leeds

Related stories:

Global study shows telmisartan reduces outcome of cardiovascular death, heart attack or stroke
An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.
Will screening for cardiovascular problems be effective?
Last week the government in England closed its consultation on the effectiveness of vascular checks for high-risk individuals aged 40-74, to be rolled out in 2009-10, but will this strategy be worthwhile? Experts debate the issue on bmj.com today.
FDA investigates possible Vytorin link to cancer
(AP) -- Federal drug safety regulators said Thursday they are investigating whether the cholesterol-lowering drug Vytorin can increase patients' risk of developing cancer.
Lowering cholesterol early in life could save lives
(PhysOrg.com) -- With heart disease maintaining top billing as the leading cause of death in the United States, a team of University of California, San Diego School of Medicine physician-researchers is proposing that aggressive intervention to lower cholesterol levels as early as childhood is the best approach available today to reducing the incidence of coronary heart disease.
Kidney disease linked to lower medication use after heart attack
Patients with kidney disease—especially end-stage renal disease (ESRD) requiring dialysis—are less likely to receive recommended medications after a heart attack, reports a study in the September 2008 Clinical Journal of the American Society of Nephrology (CJASN).
Low levels of good cholesterol linked to memory loss, dementia risk
Low levels of high-density lipoproteins (HDL) — the "good" cholesterol — in middle age may increase the risk of memory loss and lead to dementia later in life, researchers reported in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.
Gene variation may be why some don't respond to cholesterol-lowering drugs
A variation in the way the body processes a single protein may explain why some people don't respond well to drugs that lower "bad" cholesterol, according to a report in Circulation: Journal of the American Heart Association.
Unexpected finding of molecule's dual role in mice may open new avenue to cholesterol reduction
Researchers have discovered an unknown regulator of fat and cholesterol production in the liver of mice, a significant finding that could lead to new therapies for lowering unhealthy blood levels of cholesterol and fats.

News discussion:

Medicine & Health news